British pharmaceutical company GSK has announced plans to invest $30 billion in the United States over the next five years. The investment, revealed on the first day of U.S. President Donald Trump’s state visit to Britain, aims to enhance GSK’s research and development capabilities and expand its production capacities in the United States. This significant commitment comes as drugmakers face increasing pressure from President Trump to boost domestic production.
President Trump has imposed tariffs on various industries in an effort to reduce the country’s trade deficit, which he considers “unfair.” The pharmaceutical sector is among those affected, with the administration urging companies to increase U.S. manufacturing. In response, GSK’s investment will include the construction of a $1.2 billion biologics factory in Pennsylvania, focused on developing treatments for respiratory and cancer diseases. The company will also develop artificial‑intelligence capabilities at its five U.S. manufacturing sites.
The move is expected to create hundreds of highly skilled jobs, adding to the 15,000 employees GSK already has in the United States. The announcement coincides with President Trump’s state visit to the UK, a rare privilege extended by King Charles III, which highlights the long‑standing relationship between the two countries, particularly in science and healthcare innovation. As GSK chief Emma Walmsley noted, “This week’s state visit brings together two countries that have led the world in science and healthcare innovation.”
GSK’s commitment to investing in the United States underscores the importance of the U.S. pharmaceutical market and the company’s desire to strengthen its presence there. The investment is expected to bolster GSK’s position in the U.S. market while contributing to the country’s goal of increasing domestic production. With this substantial investment, GSK demonstrates its dedication to advancing healthcare innovation and creating new opportunities in the United States.
Comments are closed for this story.